Momentum is building to reevaluate the safety of pain relievers like Celebrex amid concerns of heart risks similar to Vioxx.
Researchers warn that these drugs may block substances that prevent heart problems.
The FDA's handling of Vioxx's withdrawal raises questions about drug safety monitoring.
Merck's decision to withdraw Vioxx highlights flaws in the current system.
Concerns extend to other drugs like Pfizer's Celebrex.
The debate over COX-2 inhibitors continues, with Bextra also under scrutiny.
Pfizer issues a warning about Bextra's potential heart risks.
The focus remains on improving drug safety monitoring and regulation.
